Re: Amendment #10 to Sponsored Research Agreement (SRA) dated June 10, 2015 and effective July 1, 2015, further modified in Amendment #1 to a start date of July 15, 2015 and modified subsequently as Amendments #2-9

Dear Dr. Goodman: 

Pursuant to your recent communication (email attached dated September 19, 2018) in which you notified MMRI of a change of your organization's name, MMRI provides the following amendment in order to accommodate and pursue our research activities. The following modification to our Agreement is presented as Amendment #10. 

Effective October I, 2018 it is noted that, ClearLight Diagnostics, LLC is to operate as ClearLight Biotechnologies, LLC.

428 Oakmead Parkway Sunnyvale, CA 94085
Telephone (408) 523-6260 FAX (408) 523-6261

February 9, 2021

Al Hansen

President

Clearlight Biotechnologies, Inc.

MMRI Building

428 Oakmead Parkway

Sunnyvale, CA 94085

Re: Amendment #11 to Sponsored Research Agreement (SRA) dated June 10, 2015 and effective July 1, 2015, further modified in Amendment #1 to a start date of July 15, 2015 and modified subsequently as Amendments #2-10

Dear Mr. Hansen:

Pursuant to your recent communication in which you notified MMRI of a change of your organization's name, MMRI provides the following amendment in order to accommodate and pursue our research activities. The following modification to our Agreement is presented as Amendment #11.

Effective February 9, 2021 it is noted that, ClearLight Biotechnologies, LLC is to operate as Clearlight Biotechnologies, Inc.

Sincerely yours,

Edward P Amento, MD

Executive Director and President

428 Oakmead Parkway Sunnyvale, CA 94085

Telephone (408) 523-6260 FAX (408) 523-6261

August 16, 2021

Mr. Al Hansen

President

ClearLight Biotechnologies, Inc.

428 Oakmead Parkway

Sunnyvale, CA 94085

Re: Amendment #12 to Sponsored Research Agreement (SRA) dated June 10, 2015 and effective July 31, 2016, further modified in Amendment #1 to a start date of July 15, 2015 and modified subsequently from December 9, 2015 though Amendments #2-11.

Dear Mr. Hansen:

Pursuant to our recent conversation in which you requested an amendment to our Sponsored Research Agreement of June 10, 2015 the following modification to our Agreement is presented as Amendment #12.

To facilitate our collaborative research projects, MMRI will provide additional laboratory space necessary for one additional laboratory research scientist from ClearLight Biotechnologies, Inc. ("ClearLight") to work with MMRI personnel at the Institute from August16, 2021 until the termination of our Agreement. This Amendment #12 to the Agreement of June 10, 2015 will commence as of August 16, 2021.

In consideration of the additional commitment by MMRI, ClearLight shall pay MMRI an additional research fee of $4,000.00 per month paid at the first of each month. The total monthly Sponsored Research Fee due beginning September 1, 2021 will be $14,500.00. The prorated fee for the additional laboratory research scientist for August 16-31 will be $2,000.

Please note that that monthly Sponsored Research Fee is due three (3) business days before the first (1^st) day of the month, and no later than the first (1^st) day of the month.

An additional Initial Research Fee of $8000.00 is due September 1, 2021. Therefore, the total funds due to MMRI on September 1, 2021 will be $16,500 + $8,000.

To clarify, please note that for each new research scientist participating in our Sponsored Research Agreement a new amendment is generated and there will be an additional Initial Sponsored Research Fee equal to twice the monthly Sponsored Research Fee.

428 Oakmead Parkway Sunnyvale, CA 94085

Telephone (408) 523-6260 FAX (408) 523-6261

The Initial Research Fee will be refunded, upon payment by ClearLight of all amounts owed to MMRI as noted in Section 2a of our Sponsored Research Agreement of June 10, 2015.

This Amendment #12 to the Sponsored Research Agreement of June 10, 2015 does not alter the conditions set forth in our June 10, 2015 Agreement except as modified by Amendments #1-12.

Please indicate your acceptance of this Amendment #12 to the Sponsored Research Agreement of June 10, 2015 by signing below and returning it to our office.

Sincerely yours,

Edward P Amento, MD
Executive Director

AGREED AND ACCEPTED: